Combination With Gemcitabine in Advanced Pancreatic Cancer

Inclusion Criteria: * Male or female patients ≥18 years of age * Histological or cytologically confirmed locally advanced, inoperable or metastatic pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery * Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to RECIST, Version 1.1 * Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCAE) Grade \</= 1 * Eastern Cooperative Oncology Group performance status (ECOG PS) \</= 2 * Patient has cardiac function, within normal range, as measured by an echocardiogram Exclusion Criteria: * Known history of, or symptomatic metastatic brain or meningeal tumors * History of cardiac disease * Active clinically serious infections * Clinically significant (ie. symptomatic) peripheral vascular disease * Pregnant or lactating women; women of childbearing potential not employing adequate contraception * Use of strong inhibitors or inducers of CYP3A4 * Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or other malignancy * Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers to radiation therapy in adjuvant intention if given within 6 months from start of study treatment * Thrombotic or embolic events such within 6 months prior to start of study treatment